Fiducial Marker Placement Using Endobronchial Ultrasound and Navigational Bronchoscopy for Stereotactic Radiosurgery: An Alternative Strategy
|
|
- Amice Dawson
- 6 years ago
- Views:
Transcription
1 Fiducial Marker Placement Using Endobronchial Ultrasound and Navigational Bronchoscopy for Stereotactic Radiosurgery: An Alternative Strategy Daniel P. Harley, MD, William S. Krimsky, MD, Saiyad Sarkar, MD, David Highfield, PhD, Cengis Aygun, MD, and Burak Gurses, MD Divisions of Thoracic Surgery and Radiation Oncology, Franklin Square Hospital, and Division of Pulmonary Medicine, Pulmonary and Critical Care Associates of Baltimore (PCCAB), Baltimore, Maryland Background. Stereotactic radiosurgery is being increasingly used to treat patients with early-stage non-small cell lung cancers (NSCLC) who are not candidates for surgical resection. Stereotactic radiosurgery usually needs fiducial markers (FMs) for the tracking process. FMs have generally been placed using percutaneous computed axial tomography scan guidance. We report the results of FM placement using endobronchial ultrasound (EBUS) in 43 patients. Methods. A multidisciplinary tumor board evaluates NSCLC patients before they are offered stereotactic radiosurgery. In patients selected for stereotactic radiosurgery, FMs were inserted into peripheral, central, and mediastinal tumors using EBUS and, in selected patients, navigational bronchoscopy. Patients underwent repeat computed axial tomography chest scans 2 weeks later to ensure stability of the FMs before beginning stereotactic radiosurgery. Results. Included were 43 consecutive patients (21 men, 22 women; mean age, 74.4 years). Forty-two (98%) had NSC carcinomas (5 recurrences); 1 had a carcinoid tumor. Twenty-two tumors were located in the left lung, 19 in the right lung, 1 at the carina, and 1 pretracheal. Two to 5 FMs were placed in and around all tumor masses using EBUS and, for peripheral lesions, EBUS combined with navigational bronchoscopy. Thirty patients had no displacement of FMs. In the 13 who had displaced 1 or more FMs, the ability to use the remaining FMs for stereotactic radiosurgery was unimpaired. Conclusions. EBUS and navigational bronchoscopy are safe and effective methods to position FMs for preparing patients with both central and peripheral lung cancers for stereotactic radiosurgery. (Ann Thorac Surg 2010;89:368 74) 2010 by The Society of Thoracic Surgeons Lung cancer is a global epidemic. In 2002 there were 1.35 million new cases of lung cancer causing 1.18 million deaths [1]. The United States has been a major contributor to these statistics. In 2004 an estimated 358,128 Americans were living with lung cancer. In 2007 an estimated 213,380 new cases were diagnosed, and about 160,392 Americans were expected to die of lung cancer. Approximately 16% of the patients are diagnosed with early-stage lung cancer [2], and theoretically, most of these patients would be candidates for a potentially curative resection. Many of patients with lung cancer are afflicted with severe smoking-induced morbidities such as chronic obstructive pulmonary disease (COPD), and arteriosclerotic heart disease that will preclude any attempts at curative resection. Some will have severe age-related disabilities, and some who would be physiologically able to tolerate the operation will refuse despite impartial presentation of evidence that surgical resection of lung Accepted for publication Sept 17, Presented at the Forty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Francisco, CA, Jan 26 28, Address correspondence to Dr Krimsky, 9103 Franklin Square Dr, Ste 300, Baltimore, MD 21237; william.krimsky@medstar.net. cancer is the optimal method for achieving long-term survivorship [3]. The evolution of newer radiosurgical and bronchoscopic technologies is offering alternatives for the diagnosis and treatment of thoracic malignancies. Stereotactic radiosurgery (SRS) was originally designed as a neurosurgical tool in the 1950s [4], but because of the need for a rigid compression device to limit respiration and a rigid immobilization frame for the thorax [5, 6], it was not used for treatment of lung tumors. The Cyberknife with Synchrony (Accuray Robotic Radiosurgery Systems, Accuray Inc, Sunnyvale, Ca) overcame these difficulties. It did not need an immobilizing frame and allowed for real time respiratory tracking [7, 8]. However, small metallic markers called fiducials (FMs) need to be inserted in or near the target tumor to ensure the accuracy of the delivered radiation dose [9, 10]. The insertion of FMs with minimal morbidity has been problematic. They have been inserted percutaneously using computed tomography (CT) guidance, which has resulted in a pneumothorax rate of at least 13% [11]. This percentage may be low, because CT-guided biopsies have reported pneumothorax rates of 23% to 38% [12, 13], 2010 by The Society of Thoracic Surgeons /10/$36.00 Published by Elsevier Inc doi: /j.athoracsur
2 Ann Thorac Surg HARLEY ET AL 2010;89: FIDUCIAL MARKER PLACEMENT FOR SRS Abbreviations and Acronyms ASHD arteriosclerotic heart disease CKS cyberknife with synchrony COPD chronic obstructive pulmonary disease CT computerized tomography DICOM digital imaging and communications in medicine EBUS endobronchial ultrasound ENB electromagnetic navigational bronchoscopy FFB flexible fiberoptic bronchoscopy FM fiducial markers NSCLC non-small cell lung cancer SRS stereotactic radiosurgery and a more recent series of FM placements using CT guidance reported an incidence of 48% needing pigtail catheter treatment of the pneumothoraces [14]. Flexible fiberoptic bronchoscopy has been used for the placement of FMs, but can result in FM embolization or inadvertent early deployment of the FM [15]. Although flexible fiberoptic bronchoscopy is useful in accessing central lung lesions, it has severe limitations in accessing lesions at the periphery of the lung [16, 17]. At the onset of developing our SRS program, we elected to use endobronchial ultrasound (EBUS) and electromagnetic navigational bronchoscopy (ENB) to minimize the morbidity associated with positioning FMs while simultaneously increasing the number of usable FMs. Between February 2007 and June 2008, 391 patients with histologically proven bronchogenic carcinomas were evaluated for treatment at the Franklin Square Hospital Center in Baltimore, Maryland. The patients were reviewed at multidisciplinary thoracic tumor board before being considered for thoracic SRS. Patients with a forced expiratory volume in one second of less than 40% and a diffusion capacity of the lung of less than 40% were considered to have severe chronic obstructive pulmonary disease (COPD) and in most instances were not considered candidates for surgical resection. The Institutional Review Board of MedStar Inc, the parent corporation of the Franklin Square Hospital Center, approved the data collection and analysis of these patients and waived patient consent for this review. Material and Methods All procedures were performed by 2 interventional pulmonologists trained in both EBUS and ENB. The methodology used was developed by one of the interventional pulmonologists (W.S.K.) and was followed by both physicians. The success rate for FM placement did not differ between these 2 pulmonologists. All patients had noncontrast CT scans of the chest configured with slices of 0.6-mm thickness at 1-mm intervals in the Digital Imaging and Communications in Medicine (DICOM) format. All FM placements were 369 done with the patient under general anesthesia using the oral route. Before the start of each procedure, the patient was positioned on the electromagnetic location board (superdimension Inc, Plymouth, MN) in anticipation of the possible need for ENB. The bronchoscope was an Olympus BF-1T180, 3.0-mm working channel, adult therapeutic bronchoscope (Olympus, Tokyo, Japan). EBUS was used in all of the patients and ENB was used selectively for peripheral tumors that were difficult to access using EBUS alone. Mean time for procedures was minutes. EBUS Procedure A 20-MHz radial EBUS probe (UM-S20 20R; Olympus) was used. The miniature probe was inserted into a guide sheath and was advanced as a unit into the working channel of the bronchoscope. This was guided into the bronchus of interest. The probe was extended until the operator sensed resistance and then slowly withdrawn while scanning. Ultrasound imaging of normal air-filled alveolar tissue produces a snowstorm-like whitish appearance. In contrast, in FM placement using EBUS, solid peripheral lesions are darker and more homogeneous. When such images were seen, the target was considered to have been reached. After the peripheral lesion was localized, the probe was withdrawn, leaving the sheath either within or close to the target lesion. The FMs were then deployed through the guide sheath using fluoroscopy, if needed. In selected cases, if a peripheral lesion was difficult to reach, ENB was performed before the FMs were deployed. ENB Procedure The superdimension inreach System (superdimension Inc) was used for the ENB component of the procedures. The initial planning phase involved importing the CT scan into the software (superdimension) using the standard format. Registration points were marked by identifying five or six prominent anatomic landmarks on the virtual bronchoscopic images. The multiplanar images were used to plan a target pathway, starting from the target lesion and working toward a central airway. Endobronchial mapping was conducted, and the software generated a registration error that represents the radius of the expected difference in location between the tip of the sensor probe in the actual patient and where the tip is expected to be. The registration error could then be reduced by repositioning a misplaced landmark or by eliminating the landmarks with the greatest deviation. Navigation was completed by wedging the bronchoscope in the suspected bronchial segment and steering the sensor probe, together with the extended working channel, to the lesion using the multiplanar CT scan images and the tip-view orientation. The target was considered located when a minimum distance ( 1 cm) between the steerable probe tip and the target lesion was achieved. When navigation was completed, the steerable probe was removed. GENERAL THORACIC
3 370 HARLEY ET AL Ann Thorac Surg FIDUCIAL MARKER PLACEMENT FOR SRS 2010;89: FM Placement After EBUS confirmation, the EBUS probe was removed from the sheath and gold fiducials (351-2, 351-1; Best Medical International, Fiducial Marker Placement Using EBUS, Springfield, VA) were deployed under fluoroscopic imaging. The fiducials, sizes 0.8 5mmor0.8 3 mm, were wedged into the tip of a needle brush (NB-120; Conmed, Utica, NY) or transbronchial needle (WANG Histology Needle, MW-319; Conmed) respectively. The FM was sealed into the deployment systems using bone wax. This prevented loss of the marker before placement into the extending working channel. Once the needle brush or transbronchial needle appeared at the end of the extended working channel, the FM was deployed using the stylet from the needle systems. To ensure that the marker was embedded into a distal airway/lung parenchyma, a cytology brush (Cellebrity, 1601; Boston Scientific, Natick, MA) was used under fluoroscopic guidance. Roentgenograms were obtained after the procedure to confirm the positions of the FMs as well as the absence of iatrogenic pneumothorax. Confirmation Planning CTs were performed 10 to 14 days after FM placement and reviewed by a thoracic surgeon, radiation oncologist, and nuclear physicist to determine the feasibility of using the Cyberknife with Synchrony guided by the FMs. Results Forty-three patients (21 men and 22 women) who were a mean age of 74.4 years (range 43 to 88 years) with a histologically proven thoracic malignancy were discussed and evaluated at a multidisciplinary lung cancer tumor board before being offered bronchoscopic FM placement and SRS. FM placement was accomplished in all patients using EBUS and was supplemented by ENB in 12 patients with peripheral lesions. Severe COPD was present in 31 patients (according to criteria outlined by the American Thoracic Society), 14 had arteriosclerotic heart disease, and 12 octogenarians had an age-related disability. No patient was selected to undergo SRS as a result of refusing an operation. Non-small cell lung cancer was present in 42 of the patients, 5 were local recurrences, and 1 patient with debilitating COPD had a carcinoid. Nine tumors were centrally located and 34 were peripheral. Twenty-two cancers were located on the left, 19 were on the right, 1 was at the carina, and 1 was a pretracheal recurrence. A total of 161 FMs (average of 3.7 per patient) were deployed, and 139 (86.7%) were identified radiologically when the SRS planning CT scan was performed 2 weeks later. No loss or appreciable movement of any of the deployed FMs was noted in 30 patients (69.7%). The FMs were in or on the tumor at the time of the SRS planning CT scan in 39 patients (90.6%). The FMs that had become displaced were an average of 1.67 cm (SD, 1.15; range, 0.5 to 4.56 cm) from the targeted tumor. The mean tumor size was 2.78 (SD, 1.46 cm; range, 0.9 to 6.5 cm). No patient described FM expectoration and there was no radiologic evidence for contralateral FM aspiration. No pulmonary artery or systemic arterial embolizations were encountered. Although many of the patients experienced a small amount of blood-streaked sputum after the procedure, there were no episodes of clinically significant hemoptysis. A small pneumothorax in 1 patient necessitated placement of a pigtail catheter and hospitalization for 1 day. None of the remaining patients needed postoperative hospitalization or other endoscopic interventions. There were no anesthetic-related complications and there were no hospital readmissions before SRS began. All patients were able to undergo SRS without additional FM placement or other procedures. Comment The evolution of EBUS, ENB, and SRS represent a confluence of dissimilar but complimentary technologies that are facilitating innovative methods of treating thoracic malignancies. There is a large potential cohort of patients with early-stage lung cancer who, because of significant comorbidities such as COPD, severe cardiacrelated disease, and chronic disability, will not be physiologically capable of undergoing an operation. Historically, the early use of SRS was limited to tumors that did not move with respiration, such as in the brain and spinal cord [4]. Tumor motion in patients with lung cancer was a major obstacle for using SRS to treat thoracic cancers. To be effective, SRS has to be able to accurately deliver highly focused beams of radiation from a large number of different angles to a precisely defined area within the lung. The Cyberknife with Synchrony overcame this difficulty by using real-time respiratory motion tracking (Synchrony, Accuray Robotic Radiosurgery Systems) during SRS [6 8]. To ensure accuracy, FMs have to be placed in or near the targeted tumor so that they move with the tumor [9, 10]. If possible, they should be in separate locations and not overlap. Early in the SRS experience, FMs were placed using percutaneous CT guidance. This required a series of punctures and resulted in a predictable pneumothorax rate of 13% to 48% [12 14], and all of these patients needed pigtail catheters. Patients who have severe COPD have very limited ability to tolerate an induced pneumothorax. A pneumothorax in these patients could necessitate a closed tube thoracostomy, an unplanned hospitalization, and higher procedure costs. In contrast, only one small pneumothorax occurred in our series using ENB and EBUS for placement of FMs. The distribution of FMs using CT guidance is frequently suboptimal. Approaching centrally located lesions using this technique can be hazardous and is generally avoided. Flexible fiberoptic bronchoscopy has also been tried for the placement of FMs. This technique may be adequate for some centrally located lesions but has obvious limitations in accessing peripheral lesions,
4 Ann Thorac Surg HARLEY ET AL 2010;89: FIDUCIAL MARKER PLACEMENT FOR SRS even with fluoroscopy [14]. The manual deployment of FMs during flexible fiberoptic bronchoscopy is often difficult because no tools are specifically designed for this purpose. When flexible fiberoptic bronchoscopy was used, 12 FMs were dropped before deployment, a rate of 22% [15]. In this scenario, tumor tracking during SRS may have decreased accuracy because of poorly positioned FMs. One pulmonary artery embolization occurred during FM deployment [15]. Although it was clinically insignificant, it does illustrate one of the limitations and potential dangers of placing FMs with a bronchoscopic system that is incapable of identifying pulmonary vascular structures. Deployment of a FM in a pulmonary vein could, in theory, result in a catastrophic FM embolism to any organ, including the heart and brain. Fig 1. The computed tomography scan shows fiducial placement using endobronchial ultrasound and electromagnetic navigational bronchoscopy in a peripheral lesion in a patient with severe bullous disease. (Top: lung windows. Bottom: mediastinal windows.) 371 EBUS and ENB offer a superior methodology for the placement of FMs in central and peripheral pulmonary tumors. EBUS not only identifies tumors and adjacent lymph nodes but also identifies vascular structures within the lung [18]. It identified lymph nodes 86% of the time in diagnostic procedures and achieved a diagnostic yield of 71% [19]. Tumors in the periphery of the lung can be found and biopsied without the use of fluoroscopy [20] or real-time CT imaging. Real-time CT imaging was not performed in this series, although limited fluoroscopy was used to confirm FM placement. This results in potentially lower operating costs to the institution and less radiation exposure to the bronchoscopist and staff. ENB reached peripheral tumors with a diagnostic success rate of 80.3% [21]. Combining these two modalities is advantageous in accurately identifying and biopsying peripheral lesions. The diagnostic yield when used together is significantly increased compared with using either modality alone [22]. A feasibility study of using ENB for FM placement demonstrated successful deployment in 8 of 9 patients (89%) [23]. Figure 1 demonstrates FM placement in a peripheral lesion in a patient with severe bullous disease that was approached using both EBUS and ENB. Although either is capable of providing an avenue for FM placement, the use of both in patients with peripheral lesions can result in a higher success rate. ENB helps overcome the difficulty of navigating tortuous peripheral bronchi that can be an obstacle when EBUS is used alone. EBUS can identify solid areas within the lung that may serve as FM anchors and prevent FM dislodgement. In addition, EBUS used in conjunction with ENB for placement of FMs also allows for interrogation of N1 and N2 lymph nodes during the procedure. When they are found to be positive for malignancy, an unnecessary SRS procedure on the lung can be avoided. We believe that the use of SRS is not indicated in patients with N1 nodal disease because the radiation field will be too large in patients who already have compromised lung function. Although early in our experience a patient with a tumor of 6.5 cm received SRS, we discourage its use in tumors greater than 4 cm because of potential pulmonary toxicity. The use of both EBUS and ENB results in a superior distribution of FMs and helps avoid colinear relations between FMs that can decrease the accuracy of tumor tracking during SRS. In more than 90% of the patients in this series, at least 1 FM was in the selected tumor or was very close to it. This is additional confirmation that these techniques are accurate in obtaining tissue for biopsy and marking tumors for thoracoscopic identification. The FMs used in this series were gold pellets which need a tissue anchor that is provided by the tumor mass or the adjacent lymph nodes. The technique of deployment may also cause an inflammatory reaction resulting in a small amount of fibrosis that may further stabilize the position of the FM. There was, however, a 13.3% loss rate, and this may reflect the smooth surface of the FM and their inability to achieve tissue adherence when placed in alveolar spaces. Placement of FMs within free spaces in the lung was GENERAL THORACIC
5 372 HARLEY ET AL Ann Thorac Surg FIDUCIAL MARKER PLACEMENT FOR SRS 2010;89: avoided in this series. FMs will need to be designed to achieve better tissue adherence, which will improve the ability of physicians implanting the markers to achieve conformational geometry of the implanted FM and ensure greater SRS tracking accuracy. It is important that FMs be positioned in solid structures, such as lymph nodes and the selected tumors, because FMs placed in alveolar spaces will result in a loss of the FM. To have enough FMs to ensure SRS tracking, it is necessary to implant at least 3 FMs in centrally located tumors and 4 to 5 FMs in peripheral tumors. Alternative fiducials are currently being investigated at our institution to minimize the number of attempted deployments. Although there is a very definite loss of FMs, the complication rate using EBUS and ENB for FM deployment is markedly lower than the rate using CT guidance. Although general anesthesia is not a necessity for using EBUS and ENB for FM placement, it has the distinct advantage of increasing patient comfort as well as allowing the endoscopist to communicate more freely with the assistant during a complex endoscopic procedure that lasts 1 hour at our institution. In our institution, EBUS and ENB have been performed exclusively by 2 interventional pulmonologists who were trained in this technology and used it diagnostically in several hundred cases before embarking on the SRS program and deploying a FM. This can potentially be an area of contention between invasive pulmonology and thoracic surgery colleagues and a source of turf battles. Effective use of these technologies necessitates an overall team approach with a blurring of traditional specialty barriers, and this has been facilitated by having a multidisciplinary lung cancer tumor board. The users of these technologies will vary from institution to institution, but these should not be casual procedures performed by every pulmonologist and every thoracic surgeon. Ideally, SRS should be able to be performed without the use of FMs, and there is interest in systems that can track tumors without FMs. Xsight Lung (Accuray Inc) has been designed to work with the Cyberknife with Synchrony, does not need FMs, and can target peripheral tumors with a diameter of 15 mm or greater. There are, however, significant limitations to this technology. The targeted tumors must be denser than the surrounding tissue to be recognized by the tracking system. In addition, tumors cannot be superimposed on the spine or the mediastinum radiologically for tracking to be effective. Our institution has had no patients that met these criteria. There has also been interest in Linac-based systems that do not need FMs for the treatment of lung cancers. These systems are often unable to continuously adapt to tumor motion caused by lung and diaphragm movement. Although respiratory gating helps overcome this problem, it is inadequate in many patients and will result in larger treatment margins and associated lung damage than treatments with CK. To date, a system that does not need FMs to perform stereotactic radiosurgery for lung cancer has still to be developed. The use of EBUS with the adjunctive use of ENB in selected cases for the positioning of FMs within the lung requires a team approach. There is a very definite learning curve that can be accomplished by performing diagnostic procedures with EBUS and ENB before using them to implant FMs for SRS. EBUS and ENB, utilized by experienced bronchoscopists, provide a safe and effective approach to placing pulmonary FMs for SRS and should be considered as the methodology of choice. References 1. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics Ca Cancer J Clinic 2005;55: American Lung Association. Lung cancer. Available at www. lungusa.org. 3. Ginsberg RJ, Martini N. Non-small cell lung cancer/surgical management. In: Pearson FG, Cooper JD, Deslauries J, et al, ed. Thoracic surgery. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2002: Leksill L. The stereotactic method and radiosurgery of the brain. Acta Chir Scand 1951;102: Timsnerman R, Papiez L, McGarry R, et al. Intracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124: Schweikard A, Shiomi H, Adler J. Respiration tracking in radiosurgery. Med Phys 2004;31: Adler JR, Chang SD, Murphy MJ, et al. The CyberKnife: a frameless robotic system for radiosurgery. Stereotactic Funct Neurosurg 1997;69: Kuo J, Yu C, Petrovich Z, et al. The CyberKnife stereotactic radiosurgery system: description, installation and an initial evaluation of use and functionality. Neurosurgery 2003;53: Murphy MJ. Fiducial based targeting accuracy for external beam radiotherapy. Med Phys 2002;29: Wu X, Main W, Schwade G, et al. Measurement of total clinical accuracy of an image guided radiotherapy system. Med Phys 2004;31: Whyte R, Crowner R, Murphy MJ, et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg 2003;75: Geraghty P, Kee S, McFarlane G, et al. CT-guided transthoracic needle aspiration biopsy of pulmonary nodules: needle size and pneumothorax rate. Radiology 2003;229: Yeow KM, Su IH, Pan K, et al. Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needles lung biopsies. Chest 2004;126: Pennathur A, Luketich J, Heron D, et al. Stereotactic radiosurgery for treatment of Stage I non small cell lung cancers in high risk patients. J Thorac Cardiovasc Surg 2009;137: Reichner C, Collin B, Gagnon G, et al. The placement of gold fiducials for cyberknife stereotactic radiosurgery using a modified transbronchial needle aspiration technique. J Bronchol 2005;12: Libby DM, Smith JP, Altoski NK, et al. Managing the small pulmonary nodule detected by CT. Chest 2004;125: Wallace JM, Deutsch AL. Flexible fiberoptic bronchoscopy and percutaneous needle lung aspiration or evaluating the solitary pulmonary nodule. Chest 1982;81: Becker HD, Herth F. Endobronchial ultrasound of airway and mediastinum. Bolinger CT, Mathus PN, eds. Interventional bronchoscopy. Basel, Switzerland: Karger; 2000: Herth FJ, Becker HD, Ernst A. Ultrasound-guided transbronchial needle aspiration. Chest 2003;123:604 7.
6 Ann Thorac Surg HARLEY ET AL 2010;89: FIDUCIAL MARKER PLACEMENT FOR SRS 20. Becker HD, Herth F. Endobronchial ultrasound. In: Braunwald E, Fauci AS, Isselbaches KJ, et al, eds. Harrison s principles of internal medicine monograph online, Gildea TR, Mazzone PJ, Karnak D, et al. Electromagnetic navigation diagnostic bronchoscopy: a prospective study. Am J Respir Crit Care Med 2006;174: Eberhardt R, Anantham D, Ernst A, et al. Multimodality bronchoscopic diagnosis of peripheral lung lesions. Am J Respir Crit Care Med 2007;176: Anantham D, Feller-Kopman D, Shanmugham L, et al. Electromagnetic navigation bronchoscopy guided fiducial placement for robotic stereotactic radiosurgery of lung tumors, a feasibility study. Chest 2007;132: GENERAL THORACIC DISCUSSION DR SHANDA H. BLACKMON (Houston, Texas): Dr Krimsky, did you see any tumor seeding from the endobronchial ultrasound [EBUS] placement of the fiducial going through the airway directly into a tumor adjacent to the trachea or the main stem bronchus? It might potentially pull a tumor back into that airway. Did you see any of those patients, and if you did, did they require any stenting? DR KRIMSKY: Actually, Shanda, no, we did not see that. I was able under bronchoscopic ultrasound guidance to actually place the needle in and around these areas with a great deal of specificity. So, no, we were able to avoid that. DR BLACKMON: Was there anything special you did to prevent seeding of the inside of the airway besides putting a piece of maybe the wax to push the fiducial out and prevent anything from coming back? DR KRIMSKY: No, nothing. DR MARK KRASNA (Towson, MD): I congratulate Dan on an excellent presentation. Bill, I think you should be congratulated in getting a tissue diagnosis on every one of these patients first. I think that really actually is a key, but it does lead to my second question, which maybe you and Dan together need to answer. Can you define for us in a little bit more detail what made these patients, what we will call medically inoperable, meaning some detail of the degree of their COPD [chronic obstructive pulmonary disease]. Part of what is going to be important in assessing this technology going forward prospectively with IRBs [Investigational Review Boards], like you have done, is to really come up with the common denominators of who is that patient who is too risky to undergo a resection or some other treatment. DR KRIMSKY: If you don t mind me saying, I think there is actually a second point there, which is that often we get these referrals from an outside facility, so we are pretty disciplined about making sure we restage the mediastinum either with endobronchial ultrasound or via mediastinoscopy, and that is something that actually we discuss at a tumor board ahead of time. I want to be clear about that. Then I think the other way that this is done is to make sure that these are presented at a multidisciplinary tumor board whereby thoracic surgery, pulmonology, radiology, radiation oncology, et cetera, are all present and definitions then are made at that point. So this is not decided in abstract, but rather in a public forum, if you will. DR KRASNA: Do you have PFT [pulmonary function test] data available? DR KRIMSKY: For those patients, yes, for the patients that were felt to be medically inoperable as a result of their underlying lung disabilities, yes. What they are right now, unfortunately, I don t have them off the top of my head; but regardless, as you know, these patients are often complex. I have heard folks already talking about the difference between a 19-year-old and an 86-year-old, what they look like at the door vs what their pulmonary function tests say. So I think it is a complex answer. DR PHILIP A. LINDEN (Cleveland, OH): I saw that the majority of your lesions were peripheral, I think 34 peripheral and 9 central, but you describe using EBUS, which is mainly a more central technology, to position the peripheral fiducials. Did you rely a lot on fluoroscopy as an adjunct, or how did you do it? DR KRIMSKY: No. I think it is a very astute observation. Part of it was that during that time, if you will note, electromagnetic navigational bronchoscopy [ENB] was not available, and that was during a recall period. So what we were forced to do was rely upon both virtual bronchoscopy and then using those data to inform which particular subsegments we would put a guide sheath with a radial ultrasound probe within it and then proceed to confirm position of that once we got radial ultrasound confirmation that we were in or around the lesion, and obviously we then began to use electromagnetic navigational bronchoscopy when that came back online, and for several reasons. One is that it actually allows us to put markers in various places I think more succinctly and quickly. DR LINDEN: I know no patient expectorated any fiducials, but were you able to tell on the planning CT [computed tomography] scan how many remained and how many were lost? DR KRIMSKY: I think Dr Harley actually did that. Yes, I think of the 160-something, I think they coughed out, lost whatever, and I tried to place more, obviously, knowing that there was a likelihood of losing one or two of these. DR ROBERT J. CERFOLIO (Birmingham, AL): I have two questions for you. Number one, wouldn t you agree that ENB really is the future and it is going to replace EBUS? DR KRIMSKY: I think for peripheral lesions. DR CERFOLIO: I mean even for staging the mediastinum. DR KRIMSKY: ENB vs EBUS? DR CERFOLIO: Yes. DR KRIMSKY: Actually, I would disagree with that. DR CERFOLIO: I am talking about the future now. Obviously it is going to replace it for peripheral nodules. DR KRIMSKY: Sure. DR CERFOLIO: But don t you foresee that ENB is going to maybe replace EBUS?
7 374 HARLEY ET AL Ann Thorac Surg FIDUCIAL MARKER PLACEMENT FOR SRS 2010;89: DR KRIMSKY: But is there a real-time component to ENB, and I think that is always going to be a problem. DR CERFOLIO: And the second question is the reimbursement for EBUS and ENB. Would you tell the audience the huge difference? DR KRIMSKY: Yes. Right now the reimbursement for ENB is zero, I think. Is that correct? DR CERFOLIO: But they are getting their own CPT [Current Procedural Terminology] code and the reimbursement may be up to $1,200 to $1,400, and EBUS is under $100 isn t it? DR KRIMSKY: It is $70. DR CERFOLIO: $70. So I just want to make sure the audience is listening to that very carefully and the costs difference need to be weighed so we can keep out costs down when we can. disease discovered on either ENB or EBUS who then did not proceed to stereotactic radiosurgery, but the fiducial markers were implanted, keeping in mind that those cost about $25. DR CERFOLIO: How many surgeons here in their centers are using ENB, electromagnetic navigational bronchoscopy? (A show of hands.) DR CERFOLIO: Good. How many are trying to get it in their center? (A show of hands.) DR CERFOLIO: Six, 7, 8 hands. Good. I think that it is going to take the peripheral nodule guys and put it back in our court. So I think we need to be involved in it and control it the best we can. We need to buy it, we need to own it, and we need to market it. I hate to say it, but that s the reality of our specialty and life. DR KRIMSKY: Yes, yes. Thank you very much. DR JESSICA S. DONINGTON (New York, NY): How long do these procedures take? DR KRIMSKY: What we are doing the entire procedure, EBUS and the electromagnetic navigational bronchoscopy about an hour. It is relatively quick. We do a lot of these. You know, we are able to stage the mediastinum. We do put the fiducial markers in. One thing that I don t think has been made clear is we had about 7 patients who actually had N1 or N2 nodal DR KRIMSKY: If you want to learn, please come to Franklin Square. We are happy to teach. There is a lot of folks who have already come. DR DONINGTON: I would like to make one more comment on that paper. I think this work nicely demonstrates the value of collaboration with our peers in the diagnosis and staging of early-stage lung cancer. I commend both of you on the very nice presentation. DR CERFOLIO: I agree.
Owing to the recent attention given to lung cancer
Electromagnetic : A Surgeon s Perspective Todd S. Weiser, MD, Kevin Hyman, MD, Jaime Yun, MD, Virginia Litle, MD, Cythinia Chin, MD, and Scott J. Swanson, MD Department of Cardiothoracic Surgery, Mount
More informationSubject: Virtual Bronchoscopy and Electromagnetic Navigational Bronchoscopy for Evaluation of Peripheral Pulmonary Lesions
Subject: Virtual Bronchoscopy and Electromagnetic Navigational Bronchoscopy for Evaluation of Peripheral Pulmonary Lesions Original Effective Date: 8/25/14 Policy Number: MCP-206 Revision Date(s): Review
More informationCorporate Medical Policy Electromagnetic Navigation Bronchoscopy
Corporate Medical Policy Electromagnetic Navigation Bronchoscopy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: electromagnetic_navigation_bronchoscopy 1/2010 3/2017 3/2018 9/2017
More informationElectromagnetic Navigation Bronchoscopy
Medical Policy Manual Surgery, Policy No. 179 Electromagnetic Navigation Bronchoscopy Next Review: March 2018 Last Review: March 2017 Effective: May 1, 2017 IMPORTANT REMINDER Medical Policies are developed
More informationMEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES DESCRIPTION. Page: 1 of 6
Page: 1 of 6 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY Policy Number 6.01.40 Category Technology Assessment Effective Date 04/21/11 Revised Date
More informationElectromagnetic Navigation Bronchoscopy
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationIntroduction to Interventional Pulmonology
Introduction to Interventional Pulmonology Alexander Chen, M.D. Director, Interventional Pulmonology Assistant Professor of Medicine and Surgery Divisions of Pulmonary and Critical Care Medicine and Cardiothoracic
More informationElectromagnetic Navigation Bronchoscopy. Populations Interventions Comparators Outcomes Individuals: With suspicious pulmonary lesion(s)
Protocol Electromagnetic Navigation Bronchoscopy Medical Benefit Effective Date: 04/01/13 Next Review Date: 01/20 Preauthorization No Review Dates: 09/10, 09/11, 01/12, 01/13, 01/14, 01/15, 01/16, 01/17,
More informationElectromagnetic navigational bronchoscopy in patients with solitary pulmonary nodules
Original article Electromagnetic navigational bronchoscopy in patients with solitary pulmonary nodules Samuel Copeland MD, Shrinivas Kambali MD, Gilbert Berdine MD, Raed Alalawi MD Abstract Background:
More informationErica Giblin, MD Holy Family Hospital
Erica Giblin, MD Holy Family Hospital Electromagnetic Navigation Bronchoscopy A New Treatment for Patients with Peripheral Lung Lesions Lung Cancer: An Epidemic? In the U.S.: #1 cause of cancer-related
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationPolicy #: 400 Latest Review Date: June 2016
Name of Policy: Electromagnetic Navigational Bronchoscopy Policy #: 400 Latest Review Date: June 2016 Category: Surgery Policy Grade: B Background/Definitions: As a general rule, benefits are payable under
More informationElectromagnetic Navigation Bronchoscopy
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationElectromagnetic Navigation Bronchoscopy
Electromagnetic Navigation Bronchoscopy Policy Number: 7.01.122 Last Review: 9/2018 Origination: 1/2010 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationElectromagnetic Navigation Bronchoscopy
Electromagnetic Navigation Bronchoscopy Policy Number: 7.01.122 Last Review: 9/2017 Origination: 1/2010 Next Review: 9/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationLung cancer forms in tissues of the lung, usually in the cells lining air passages.
Scan for mobile link. Lung Cancer Lung cancer usually forms in the tissue cells lining the air passages within the lungs. The two main types are small-cell lung cancer (usually found in cigarette smokers)
More informationUNDERSTANDING SERIES LUNG CANCER BIOPSIES LungCancerAlliance.org
UNDERSTANDING SERIES LUNG CANCER BIOPSIES 1-800-298-2436 LungCancerAlliance.org CONTENTS What is a Biopsy?...2 Non-Surgical Biopsies...3 Surgical Biopsies...5 Biopsy Risks...6 Biopsy Results...6 Questions
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationNavigational bronchoscopy-guided dye marking to assist resection of a small lung nodule
Case Report on Aerodigestive Endoscopy Navigational bronchoscopy-guided dye marking to assist resection of a small lung nodule Jennifer L. Sullivan 1, Michael G. Martin 2, Benny Weksler 1 1 Division of
More informationInterventional Pulmonology
Interventional Pulmonology The Division of Thoracic Surgery Department of Cardiothoracic Surgery New York Presbyterian/Weill Cornell Medical College p: 212-746-6275 f: 212-746-8223 https://weillcornell.org/eshostak
More informationStereotactic Radiosurgery. Extracranial Stereotactic Radiosurgery. Linear accelerators. Basic technique. Indications of SRS
Stereotactic Radiosurgery Extracranial Stereotactic Radiosurgery Annette Quinn, MSN, RN Program Manager, University of Pittsburgh Medical Center Using stereotactic techniques, give a lethal dose of ionizing
More informationBronchoscopy and endobronchial ultrasound for diagnosis and staging of lung cancer
FRANCISCO AÉCIO ALMEIDA, MD, MS, FCCP Associate Staff Member, Director, Interventional Pulmonary Medicine Fellowship Program, Respiratory Institute, Cleveland Clinic, Cleveland, OH Bronchoscopy and endobronchial
More informationStandardized transbronchial needle aspiration procedure for intrathoracic lymph node staging of non-small cell lung cancer
Original Article on Transbronchial Needle Aspiration (TBNA) Standardized transbronchial needle aspiration procedure for intrathoracic lymph node staging of non-small cell lung cancer Xu-Ru Jin 1 *, Min
More informationADVANCED LUNG DIAGNOSTICS
ADVANCED LUNG DIAGNOSTICS SAMIR S. MAKANI, MD, FCCP DIRECTOR INTERVENTIONAL PULMONARY AND BROCHOSCOPY UNIVERSITY OF CALIFORNIA SAN DIEGO MEDICAL CENTER SAN DIEGO, CA Dr. Samir Makani is an Associate professor
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationThe Effect of Respiratory Motion on Pulmonary Nodule Location During Electromagnetic Navigation Bronchoscopy
[ Original Research Pulmonary Procedures ] The Effect of Respiratory Motion on Pulmonary Nodule Location During Electromagnetic Navigation Bronchoscopy Alexander Chen, MD ; Nicholas Pastis, MD, FCCP ;
More informationUpdate on Navigational Bronchoscopy: Electromagnetic Navigation Bronchoscopy
Update on Navigational Bronchoscopy: Electromagnetic Navigation Bronchoscopy and Lung Point 28.02.15 The Prince Charles Hospital University of Queensland Thoracic Research Center AUSTRALIA The Prince Charles
More informationWhat is the CyberKnife System?
CYBERKNIFE Robotic Radiosurgery System PATIENT BROChURE What is the CyberKnife System? have stabilizing frames bolted to their head or limit their breathing during treatment to minimize movement of the
More informationGold Anchor enables safe reach to inner organs
Gold Anchor enables safe reach to inner organs Fine needles for cytology have been used >50 years in all parts of the human body with no to very little harm Gold Anchor comes pre-loaded in needles of the
More informationLess Invasive Options for Pulmonary Testing
Less Invasive Options for Pulmonary Testing Guest Expert: Jonathan, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with doctors Francine Foss and Lynn. I am Bruce Barber.
More informationInnovations in Lung Cancer Diagnosis and Surgical Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationInformation for. Patients with an Abnormal Lung X-ray
Information for Patients with an Abnormal Lung X-ray Some of the materials in this resource were adapted with permission from: Understanding Lung Cancer, Juravinski Cancer Centre, Hamilton Health Sciences,
More informationLung Cancer Resection
Lung Cancer Resection Introduction The occurrence of lung cancer has increased dramatically over the last 50 years. Your health care provider may have recommended an operation to remove your lung cancer.
More informationThoracoscopy for Lung Cancer
Thoracoscopy for Lung Cancer Introduction The occurrence of lung cancer has increased dramatically over the last 50 years. Your doctor may have recommended an operation to remove your lung cancer. The
More informationElectromagnetic Navigation Bronchoscopy Performed by Thoracic Surgeons: One Center s Early Success
Electromagnetic Navigation Bronchoscopy Performed by Thoracic Surgeons: One Center s Early Success Daryl Phillip Pearlstein, MD, Curtis C. Quinn, MD, Charles C. Burtis, BS, Kwang Woo Ahn, PhD, and Aaron
More informationAdvanced Tumor Treatment
Advanced Tumor Treatment What is CyberKnife? The CyberKnife Stereotactic Radiosurgery System, offered by Southwest Washington Medical Center, is a noninvasive outpatient treatment without the risks and
More informationSince central airway stenosis is often a lifethreatening. Double Y-stenting for tracheobronchial stenosis. Masahide Oki and Hideo Saka
Eur Respir J 2012; 40: 1483 1488 DOI: 10.1183/09031936.00015012 CopyrightßERS 2012 Double Y-stenting for tracheobronchial stenosis Masahide Oki and Hideo Saka ABSTRACT: The purpose of the present study
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationEndoscopy. Pulmonary Endoscopy
Pulmonary 1 Direct visualization of TB tree Developed in 1890 s to remove foreign bodies - rigid metal tube Advances added light system, Sx Flexible fiberoptic scopes introduced in early 1960 s 2 Used
More informationRole of electromagnetic navigational bronchoscopy in pulmonary nodule management
Review Article Role of electromagnetic navigational bronchoscopy in pulmonary nodule management Aditya Goud 1, Chanukya Dahagam 1, David P. Breen 2, Saiyad Sarkar 3 1 Department of Internal Medicine, MedStar
More informationEffect of Electromagnetic Navigation on CT-Guided Percutaneous Thermal Ablation or Biopsy of Lung Tumors
Effect of Electromagnetic Navigation on CT-Guided Percutaneous Thermal Ablation or Biopsy of Lung Tumors Chaitan K. Narsule 1, Avneesh Gupta 2, Michael I. Ebright 1, Ricardo Sales dos Santos 3, Roberto
More informationBRONCHOSCOPY AND ASSOCIATED PROCEDURE CODING IN ICD-10-PCS AND CPT
BRONCHOSCOPY AND ASSOCIATED PROCEDURE CODING IN ICD-10-PCS AND CPT WHY AND HOW IS A BRONCHOSCOPY PERFORMED? A bronchoscopy is a test to view the airways and diagnose lung disease. It may also be used during
More informationEndobronchial Ultrasound for Diagnosis and Staging of Lung Cancer
Endobronchial Ultrasound for Diagnosis and Staging of Lung Cancer Policy Number: 6.01.58 Last Review: 08/2017 Origination: 08/2015 Next Review: 08/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationX-Ray Guided Robotic Radiosurgery for Solid Tumors
X-Ray Guided Robotic Radiosurgery for Solid Tumors Mohan Bodduluri Accuray Incorporated 570 Del Rey Avenue Sunnyvale, CA 94085 USA and J. M. McCarthy Department of Mechanical and Aerospace Engineering
More informationDouble Y-stenting for tracheobronchial stenosis
ERJ Express. Published on April 10, 2012 as doi: 10.1183/09031936.00015012 Double Y-stenting for tracheobronchial stenosis M. Oki and H. Saka AFFILIATIONS Dept of Respiratory Medicine, Nagoya Medical Center,
More informationSee it! Trust it! Treat it!
Flexible soft tissue Marker for IGRT, SBRT & PT See it! Trust it! Treat it! THORACIC GI GU CERVIX See it! Improved Marker Visibility by Design Conventional gold seeds VISICOIL linear fiducial marker 1)
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal
More informationExpert Round Table with Drs. Anne Tsao and Alex Farivar Part 1: Elderly Man with Indolent Bronchioloalveolar Carcinoma
Expert Round Table with Drs. Anne Tsao and Alex Farivar Part 1: Elderly Man with Indolent Bronchioloalveolar Carcinoma February 2010 I d like to welcome everyone, thanks for coming out to our lunch with
More informationInterventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600
Endobronchial valve insertion to reduce lung volume in emphysema Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600 Your responsibility This guidance represents
More informationPneumothorax Post CT-guided Fine Needle Aspiration Biopsy for Lung Nodules: Our Experience in King Hussein Medical Center
Pneumothorax Post CT-guided Fine Needle Aspiration Biopsy for Lung Nodules: Our Experience in King Hussein Medical Center Ala Qayet MD*, Laith Obaidat MD**, Mazin Al-Omari MD*, Ashraf Al-Tamimi MD^, Ahmad
More informationMay-Lin Wilgus. A. Study Purpose and Rationale
Utility of a Computer-Aided Diagnosis Program in the Evaluation of Solitary Pulmonary Nodules Detected on Computed Tomography Scans: A Prospective Observational Study May-Lin Wilgus A. Study Purpose and
More informationTests Your Pulmonologist Might Order. Center For Cardiac Fitness Pulmonary Rehab Program The Miriam Hospital
Tests Your Pulmonologist Might Order Center For Cardiac Fitness Pulmonary Rehab Program The Miriam Hospital BASIC ANATOMY OF THE LUNGS Lobes of Lung 3 lobes on the Right lung 2 lobes on the Left Blood
More informationCharlton Campus Map Information Handbook
Charlton Campus Map Information Handbook 50 Charlton Avenue East Hamilton, Ontario, L8N 4A6 S Parking Garage Public Parking W N Walkway to Hospital Fontbonne for patients and families Staff Only Parking
More informationRadial endobronchial ultrasound (EBUS), performed during
Original Article Can Computed Tomography Characteristics Predict Outcomes in Patients Undergoing Radial Endobronchial Ultrasound-Guided Biopsy of Peripheral Lung Lesions? Matthew Evison,* Philip A.J. Crosbie,*
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationXSIGHT LUNG TRACKING SYSTEM
XSIGHT LUNG TRACKING SYSTEM CYBERKNIFE SYSTEM HIGHLIGHTS Continual image guidance Without the need for staff intervention or treatment interruption, the CyberKnife s revolutionary image guidance technology
More informationTransbronchial fine needle aspiration
Thorax 1982;37 :270-274 Transbronchial fine needle aspiration J LEMER, E MALBERGER, R KONIG-NATIV From the Departments of Cardio-thoracic Surgery and Cytology, Rambam Medical Center, Haifa, Israel ABSTRACT
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationRadiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer
Radiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer Poster No.: C-0654 Congress: ECR 2011 Type: Scientific Paper Authors:
More informationEndobronchial valve insertion to reduce lung volume in emphysema
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Endobronchial valve insertion to reduce lung volume in emphysema Emphysema is a chronic lung disease that
More informationJMSCR Vol 06 Issue 03 Page March 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-4 DOI: https://dx.doi.org/.18535/jmscr/v6i3.63 Diagnostic Role of FOB in Radiological
More informationThe Various Methods to Biopsy the Lung PROF SHITRIT DAVID HEAD, PULMONARY DEPARTMENT MEIR MEDICAL CENTER, ISRAEL
The Various Methods to Biopsy the Lung PROF SHITRIT DAVID HEAD, PULMONARY DEPARTMENT MEIR MEDICAL CENTER, ISRAEL Conflict of Interest This presentation is supported by AstraZeneca Two main steps before
More informationStereotactic Body Radiotherapy for Lung Lesions using the CyberKnife of-the-art and New Innovations
Stereotactic Body Radiotherapy for Lung Lesions using the CyberKnife State-of of-the-art and New Innovations Chad Lee, PhD CK Solutions, Inc. and CyberKnife Centers of San Diego Outline Basic overview
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Virtual Bronchoscopic Navigation Improves the Diagnostic Yield of Radial-Endobronchial Ultrasound for Peripheral Pulmonary Lesions with Involved Bronchi on CT Fumihiro Asano 1, Naofumi
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationThoracic Diagnostic Assessment Program. Patient information for. Last revised: November
Thoracic Diagnostic Assessment Program Patient information for Last revised: November 2016 1 A list of your tests and appointments Diagnostic tests 2 3 4 Specialist appointments Doctor: Specialty: Notes:
More informationENDOBRONCHIAL ABLATIVE THERAPIES. Christopher Cortes, MD, FPCCP
ENDOBRONCHIAL ABLATIVE THERAPIES Christopher Cortes, MD, FPCCP Choice of Ablative Therapy Size of the lesion Location of the lesion Characteristics of the lesion Availability of the different therapies
More informationSubject: Computer Assisted Surgical Navigation
02-99221-14 Original Effective Date: 03/15/09 Reviewed: 08/23/18 Revised: 09/15/18 Subject: Computer Assisted Surgical Navigation THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Small cell lung cancer (SCLC) affects 15% of all lung cancer patients. SCLC is the most aggressive type of lung cancer. It may be treated with chemotherapy and radiation. SCLC has
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationCyberKnife Technology in Ablative Radiation Therapy. Jun Yang PhD Cyberknife Center of Philadelphia Drexel University Jan 2017
CyberKnife Technology in Ablative Radiation Therapy Jun Yang PhD Cyberknife Center of Philadelphia Drexel University Jan 2017 Objectives Components and work flow of CyberKnife Motion management of CyberKnife
More informationAccurate mediastinal staging is a critical component
Endobronchial Ultrasound for Lung Cancer Staging: How Many Stations Should Be Sampled? Mark I. Block, MD Thoracic Surgery, Memorial Healthcare System, Hollywood, Florida Background. No guidelines exist
More informationCyberknife of Long Island Robotic Radiosurgery at North Shore Radiation Therapy
Cyberknife of Long Island Robotic Radiosurgery at North Shore Radiation Therapy Setting the standard for innovative, compassionate cancer treatment What is the Cyberknife System? The Cyberknife Robotic
More informationGROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding:
GROUP 1: Including: Excluding: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases Solid pulmonary nodules 8mm diameter / 300mm3 volume and BROCK risk of malignancy
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More information2015 Radiology Coding Survival Guide
2015 Radiology Coding Survival Guide Chapter 31: Clinical Brachytherapy (77750-77799) Clinical brachytherapy involves applying radioelements into or around a treatment field. CPT guidelines clarify that
More informationPrecisely Maximize Dose, side effects, Patient
Precisely Maximize Dose, Minimize side effects, Maximize Patient Comfort Key Differentiators: The CyberKnife M6 Series Industry-leading precision and patient comfort Enables full-body robotic radiosurgery,
More informationNew Horizons in the Imaging of the Lung
New Horizons in the Imaging of the Lung Postprocessing. How to do it and when do we need it? Peter M.A. van Ooijen, MSc, PhD Principal Investigator, Radiology, UMCG Discipline Leader Medical Imaging Informatics
More informationThe diagnostic efficacy and safety of endobronchial ultrasound-guided transbronchial needle aspiration as an initial diagnostic tool
ORIGINAL ARTICLE Korean J Intern Med 2013;28.660-667 The diagnostic efficacy and safety of endobronchial ultrasound-guided transbronchial needle aspiration as an initial diagnostic tool Young Rak Choi
More information2017 Coding & Payment Quick Reference
2017 Coding & Payment Quick Reference Select Pulmonary Procedures Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding or site of service requirements.
More informationOriginal Date: April 2016 Page 1 of 7 FOR CMS (MEDICARE) MEMBERS ONLY
National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIATION THERAPY: STEREO RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: Please refer to pages 5-6 LCD
More informationWELLNESS INITIATIVE NOW
WELLNESS INITIATIVE NOW To promote personal well-being, fitness and nutrition for all TDCJ employees. November 2008 Lung cancer is cancer that forms in tissues of the lung, usually in the cells lining
More informationUpdates in Interventional Pulmonary Medicine
Updates in Interventional Pulmonary Medicine Eric J. Seeley, MD, FCCP Director of Bronchoscopy and Interventional Pulmonary Medicine Division of Pulmonary/CCM Department of Internal Medicine UCSF School
More informationLearning Objectives. Updates in Interventional Pulmonary Medicine. Brief History of IP. Brief History of IP. Who is an Interventional Pulmonologist?
Learning Objectives Who is an Interventional Pulmonologist? Updates in Interventional Pulmonary Medicine Eric J. Seeley, MD, FCCP Director of Bronchoscopy and Interventional Pulmonary Medicine Division
More informationLung Surgery: Thoracoscopy
Lung Surgery: Thoracoscopy A Problem with Your Lungs Your doctor has told you that you need surgery called thoracoscopy for your lung problem. This surgery alone may treat your lung problem. Or you may
More informationFEE RULES RADIATION ONCOLOGY FEE SCHEDULE CONTENTS
Tel: +27-21-9494060 Fax: +27-21-9494112 E-mail: leon.gouws@cancercare.co.za FEE RULES RADIATION ONCOLOGY FEE SCHEDULE CONTENTS 1. EXTERNAL BEAM RADIATION... 2 2. PLANNING OF TREATMENT... 2 3. DELIVERY
More informationYour Guide to Prostate Cancer
Your Guide to Prostate Cancer If you face a diagnosis of prostate cancer, what s next? We can help. A prostate cancer diagnosis can be overwhelming. The good news is that while prostate cancer can be serious,
More informationLung Cancer staging Role of ENDOBRONCHIAL ULTRASOUND(Ebus) EBUS
Lung Cancer staging Role of ENDOBRONCHIAL ULTRASOUND(Ebus) Arvind Perathur Winter Retreat Feb 13 th 2011 Mason City IA 50401 EBUS Tiger now offers a very economical and environmentally friendly all electric
More information4 Essentials of CK Physics 8/2/2012. SRS using the CyberKnife. Disclaimer/Conflict of Interest
SRS using the CyberKnife Sonja Dieterich, PhD, DABR Associate Professor University of California Davis Disclaimer/Conflict of Interest Consulting agreements with Broncus Medical and CyberHeart, Inc. Scientific
More informationFactors Related to Diagnostic Sensitivity Using an Ultrathin Bronchoscope Under CT Guidance*
Original Research INTERVENTIONAL PULMONOLOGY Factors Related to Diagnostic Sensitivity Using an Ultrathin Bronchoscope Under CT Guidance* Naofumi Shinagawa, MD, PhD; Koichi Yamazaki, MD, PhD; Yuya Onodera,
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationLung Cancer Screening
Scan for mobile link. Lung Cancer Screening What is lung cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease at
More informationEndobronchial ultrasound-guided lymph node biopsy with transbronchial needle forceps: a pilot study
Eur Respir J 2012; 39: 373 377 DOI: 10.1183/09031936.00033311 CopyrightßERS 2012 Endobronchial ultrasound-guided lymph node biopsy with transbronchial needle forceps: a pilot study F.J.F. Herth*, H. Schuler*,
More informationNew Radiation Treatment Modalities in the Treatment of Lung Cancer
New Radiation Treatment Modalities in the Treatment of Lung Cancer David Perry, M.D. Chief, Radiation Oncology Medical Director, CyberKnife Radiosurgery Center Medstar Franklin Square Medical Center Definitions
More information